SR 27897

CAS : 136381-85-6

Ref. 3D-LFA38185

Informations sur le produit

• Nom: SR 27897
• Synonymes: (2-{[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl}-1H-indol-1-yl)acetic acid, 1H-Indole-1-acetic acid, 2-[[[4-(2-chlorophenyl)-2-thiazolyl]amino]carbonyl]-, 2-(2-((4-(2-Chlorophenyl)thiazol-2-yl)carbamoyl)-1H-indol-1-yl)acetic acid, 2-[2-[[4-(2-Chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid hydrate, 2-[[N-[4-(2-Chlorophenyl)-2-thiazolyl]amino]carbonyl]-1H-indole-1-acetic acid, 2-[[[4-(2-Chlorophenyl)-2-thiazolyl]amino]carbonyl]-1H-indole-1-acetic acid, Lintitript, Sr 27897B, Sr-27897, [2-[4-(2-Chloro-phenyl)-thiazol-2-ylcarbamoyl]-indol-1-yl]-acetic acid

Description

SR 27897 is a novel, non-peptide, orally active agent that selectively activates the receptor for substance P. Animal studies have shown that SR 27897 has a hypoglycemic effect and can reduce food intake. The drug binds to the receptor for substance P and inhibits the release of acetylcholine from nerve terminals in the bladder, which may be due to its ability to release melatonin from pineal gland cells. It is also thought that SR 27897 may have therapeutic potential in treating cancer.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 411.86 g/mol
• Formule: C₂₀H₁₄ClN₃O₃S
• Degré de pureté: Min. 95%